Respiratory Diseases/Disorders Archives - MPR

Respiratory Diseases/Disorders

Selpercatinib Promising in RET Fusion-Positive NSCLC

Treatment with selpercatinib (LOXO-292) was associated with high objective response rate (ORR) in heavily pretreated patients with RET fusion-positive non-small cell lung cancer (NSCLC), according to research presented at the IASLC 2019 World Conference on Lung Cancer. Researchers from Memorial Sloan Kettering Cancer Center presented data from the LIBRETTO-001 (LOXO-292 Investigated to Block RETaltered Tumors)…

FDA Approves Treatment for Systemic Sclerosis-Associated Interstitial Lung Disease

The Food and Drug Administration (FDA) has approved Ofev (nintedanib; Boehringer Ingelheim) capsules as the first FDA-approved treatment to slow the rate of decline in pulmonary function in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD).  The approval was based on results from the 52-week, randomized, double-blind, placebo-controlled phase 3 SENSCIS trial that evaluated the…

Investigational Vaccine to Prevent RSV in Older Patients Gets Breakthrough Status

Janssen announced that the Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for their investigational prophylactic vaccine for the prevention of respiratory syncytial virus (RSV)-mediated lower respiratory tract disease in adults aged 60 years and older. RSV is a highly prevalent and contagious respiratory infection. It is the most common cause of bronchitis…